Status:
COMPLETED
Safety and Efficacy of Vancomycin Plus Beta-lactams
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Collaborating Sponsors:
Second Affiliated Hospital of Xi'an Jiaotong University
Conditions:
Critical Illness
Eligibility:
All Genders
18+ years
Brief Summary
The combination of vancomycin and piperacillin-tazobactam has been associated with an increased risk of acute kidney injury (AKI) in non-critically ill patient populations, but it is still unknown if ...
Detailed Description
The combination of vancomycin and piperacillin-tazobactam has been associated with an increased risk of acute kidney injury (AKI) in non-critically ill patient populations, but limited data regarding ...
Eligibility Criteria
Inclusion
- 18 years or older,
- admitted to intensive care unit
- received the combination of vancomycin and beta-lactams for at least 48 hours
- had a serum creatinine level measured within 24-hour hospital admission
- had at least one VAN level drawn while receiving a combination of study antibiotics
Exclusion
- pregnancy or lactating patients
- admission to the intensive care unit during administration or within 72 hours of completing the antibiotics
- had end-stage renal disease
- died within 48 hours of combination antibiotic therapy initiation
Key Trial Info
Start Date :
December 12 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 30 2020
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT03776409
Start Date
December 12 2018
End Date
May 30 2020
Last Update
June 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, China, 710061